Prothena (PRTA) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Prothena Revenue Highlights

Latest Revenue (Y)

$91.37M

Latest Revenue (Q)

$132.01M

Main Segment (Y)

Collaboration

Prothena Revenue by Period

Prothena Revenue by Year

Date	Revenue	Change
2023-12-31	$91.37M	69.50%
2022-12-31	$53.91M	-73.13%
2021-12-31	$200.58M	23414.30%
2020-12-31	$853.00K	4.79%
2019-12-31	$814.00K	-14.76%
2018-12-31	$955.00K	-96.53%
2017-12-31	$27.52M	2508.44%
2016-12-31	$1.05M	-34.35%
2015-12-31	$1.61M	-96.84%
2014-12-31	$50.85M	7422.78%
2013-12-31	$676.00K	-74.57%
2012-12-31	$2.66M	424.26%
2011-12-31	$507.00K	-59.21%
2010-12-31	$1.24M	-

Prothena generated $91.37M in revenue during NA 2023, up 69.50% compared to the previous quarter, and up 9567.54% compared to the same period a year ago.

Prothena Revenue by Quarter

Date	Revenue	Change
2024-06-30	$132.01M	263928.00%
2024-03-31	$50.00K	-84.18%
2023-12-31	$316.00K	-99.63%
2023-09-30	$84.87M	2011.62%
2023-06-30	$4.02M	85.29%
2023-03-31	$2.17M	-95.66%
2022-12-31	$49.92M	3190.90%
2022-09-30	$1.52M	15.63%
2022-06-30	$1.31M	13.79%
2022-03-31	$1.15M	-1.62%
2021-12-31	$1.17M	-99.16%
2021-09-30	$139.17M	131.68%
2021-06-30	$60.07M	37444.38%
2021-03-31	$160.00K	-55.56%
2020-12-31	$360.00K	129.30%
2020-09-30	$157.00K	-19.49%
2020-06-30	$195.00K	38.30%
2020-03-31	$141.00K	-44.92%
2019-12-31	$256.00K	24.88%
2019-09-30	$205.00K	22.75%
2019-06-30	$167.00K	-10.22%
2019-03-31	$186.00K	-4.12%
2018-12-31	$194.00K	-23.92%
2018-09-30	$255.00K	-8.60%
2018-06-30	$279.00K	22.91%
2018-03-31	$227.00K	-0.87%
2017-12-31	$229.00K	4.57%
2017-09-30	$219.00K	-99.18%
2017-06-30	$26.81M	10252.12%
2017-03-31	$259.00K	51.46%
2016-12-31	$171.00K	-40.21%
2016-09-30	$286.00K	-14.11%
2016-06-30	$333.00K	25.66%
2016-03-31	$265.00K	-13.68%
2015-12-31	$307.00K	-28.44%
2015-09-30	$429.00K	54.32%
2015-06-30	$278.00K	-53.12%
2015-03-31	$593.00K	-70.54%
2014-12-31	$2.01M	35.46%
2014-09-30	$1.49M	-90.17%
2014-06-30	$15.12M	-53.09%
2014-03-31	$32.23M	19201.80%
2013-12-31	$167.00K	-2.34%
2013-09-30	$171.00K	2.40%
2013-06-30	$167.00K	-2.34%
2013-03-31	$171.00K	-70.26%
2012-12-31	$575.00K	-39.09%
2012-09-30	$944.00K	28.44%
2012-06-30	$735.00K	81.93%
2012-03-31	$404.00K	-

Prothena generated $132.01M in revenue during Q2 2024, up 263928.00% compared to the previous quarter, and up 6086.40% compared to the same period a year ago.

Prothena Revenue Breakdown

Prothena Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20
Collaboration	$91.32M	$13.86M	$139.83M	$564.00K
License	$50.00K	$289.00K	-	-
US Rights and Global Rights	-	$85.30M	-	-
Collaboration Program, US Rights	-	$13.90M	$24.90M	-

Prothena's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration (99.95%), and License (0.05%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Collaboration	$970.00K	-	$316.00K	$84.87M	$4.02M	$2.12M	$9.92M	$1.52M	$1.31M	$1.10M	$1.17M	$78.48M	$60.07M	$110.00K	$121.00K	$157.00K	$145.00K
License	-	$50.00K	$40.00M	-	-	$50.00K	$239.00K	-	$50.00K	-	-	-	-	-	-	-	-
US Rights and Global Rights	-	-	-	$67.40M	$85.30M	$85.30M	$85.30M	$85.30M	$85.30M	-	-	-	-	-	-	-	-
Collaboration Program, US Rights	-	-	-	$300.00K	$67.40M	$85.30M	$24.90M	-	-	-	-	-	-	-	-	-	-
Collaboration Revenue, US Development Services	-	-	-	-	-	-	-	$21.40M	$22.90M	$24.20M	-	-	-	-	-	-	-

Prothena's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Collaboration (100.00%).

Prothena Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
KNSA	Kiniksa Pharmaceuticals	$270.26M	$112.21M
IMCR	Immunocore	$249.43M	$75.40M
MCRB	Seres Therapeutics	$126.33M	-
ACLX	Arcellx	$110.32M	$26.03M
PRTA	Prothena	$91.37M	$132.01M
SCPH	scPharmaceuticals	$13.59M	$8.05M
STOK	Stoke Therapeutics	$8.78M	$4.89M
PLRX	Pliant Therapeutics	$1.58M	-
MIST	Milestone Pharmaceuticals	$1.00M	-
LIFE	aTyr Pharma	$353.00K	$235.00K
VRDN	Viridian Therapeutics	$314.00K	$86.00K
CGEM	Cullinan Oncology	-	-
PCVX	Vaxcyte	-	-
NUVL	Nuvalent	-	-
DICE	DICE Therapeutics	-	-
MDGL	Madrigal Pharmaceuticals	-	$62.17M
VTYX	Ventyx Biosciences	-	-
ONCY	Oncolytics Biotech	-	-
ETNB	89bio	-	-

PRTA Revenue FAQ

What is Prothena’s yearly revenue?

Prothena's yearly revenue for 2023 was $91.37M, representing an increase of 69.50% compared to 2022. The company's yearly revenue for 2022 was $53.9M, representing a decrease of -73.13% compared to 2021. PRTA's yearly revenue for 2021 was $200.58M, representing an increase of 23414.30% compared to 2020.

What is Prothena’s quarterly revenue?

Prothena's quarterly revenue for Q2 2024 was $132.01M, a 263928.00% increase from the previous quarter (Q1 2024), and a 3184.75% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $50K, a -84.18% decrease from the previous quarter (Q4 2023), and a -97.69% decrease year-over-year (Q1 2023). PRTA's quarterly revenue for Q4 2023 was $316K, a -99.63% decrease from the previous quarter (Q3 2023), and a -99.37% decrease year-over-year (Q4 2022).

What is Prothena’s revenue growth rate?

Prothena's revenue growth rate for the last 3 years (2021-2023) was -54.45%, and for the last 5 years (2019-2023) was 11124.82%.

What are Prothena’s revenue streams?

Prothena's revenue streams in c 23 are Collaboration, and License. Collaboration generated $91.32M in revenue, accounting 99.95% of the company's total revenue, up 559.11% year-over-year. License generated $50K in revenue, accounting 0.05% of the company's total revenue, down -82.70% year-over-year.

What is Prothena’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Prothena was Collaboration. This segment made a revenue of $91.32M, representing 99.95% of the company's total revenue.